BIOMAT Database Logo BIOMAT Database Logo

High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients. 1993

P J Bierman, and R G Bagin, and S Jagannath, and J M Vose, and G Spitzer, and A Kessinger, and K A Dicke, and J O Armitage
Department of Internal Medicine, University of Nebraska Medical Center, Omaha.

BACKGROUND There is little long-term follow-up information after autologous transplantation for Hodgkin's disease. We evaluated the influence of various prognostic factors and examined the outcome in 128 such patients. METHODS Patients received high dose cyclophosphamide, carmustine, and etoposide followed by autologous hematopoietic rescue. RESULTS Patients have been observed between 50-130 months (median 77 months) following transplantation. Overall survival at four years is estimated as 45 percent, and failure-free survival as 25 percent. The best results were seen in patients with a good performance status, who had failed at most one prior chemotherapy regimen. Failure-free survival at four years is estimated as 53 percent for this group. Relapses more than 24 months after transplantation were seen in 11 patients. Five patients developed myelodysplastic syndromes. Three patients became pregnant after the transplant. CONCLUSIONS Prolonged failure-free survival may be observed following high dose chemotherapy and autologous hematopoietic rescue in patients with Hodgkin's disease. Superior results were seen in patients without extensive prior chemotherapy and in those with a good performance status. Late relapses and deaths from secondary myelodysplastic syndromes mandate prolonged follow-up after autologous transplantation for Hodgkin's disease.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002330 Carmustine A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed) BCNU,1,3-Bis(2-Chloroethyl)-1-Nitrosourea,BiCNU,FIVB,N,N'-Bis(2-Chloroethyl)-N-Nitrosourea,Nitrumon
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females

Related Publications

P J Bierman, and R G Bagin, and S Jagannath, and J M Vose, and G Spitzer, and A Kessinger, and K A Dicke, and J O Armitage
High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy.
February 1996, Annals of oncology : official journal of the European Society for Medical Oncology,
P J Bierman, and R G Bagin, and S Jagannath, and J M Vose, and G Spitzer, and A Kessinger, and K A Dicke, and J O Armitage
Long-term follow-up high-dose chemotherapy (drug-only program) followed by autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas.
June 2005, Clinical lymphoma,
P J Bierman, and R G Bagin, and S Jagannath, and J M Vose, and G Spitzer, and A Kessinger, and K A Dicke, and J O Armitage
Long-term follow up of high-dose chemotherapy with autologous stem cell rescue in adults with Ewing tumor.
June 2005, American journal of clinical oncology,
P J Bierman, and R G Bagin, and S Jagannath, and J M Vose, and G Spitzer, and A Kessinger, and K A Dicke, and J O Armitage
Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation.
September 2006, Leukemia,
P J Bierman, and R G Bagin, and S Jagannath, and J M Vose, and G Spitzer, and A Kessinger, and K A Dicke, and J O Armitage
High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease.
May 1993, Annals of hematology,
P J Bierman, and R G Bagin, and S Jagannath, and J M Vose, and G Spitzer, and A Kessinger, and K A Dicke, and J O Armitage
[High-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma].
January 2008, Medicina clinica,
P J Bierman, and R G Bagin, and S Jagannath, and J M Vose, and G Spitzer, and A Kessinger, and K A Dicke, and J O Armitage
High-dose chemotherapy and autologous bone marrow rescue in advanced resistant/relapsing Hodgkin's disease.
November 1989, Pathologie-biologie,
P J Bierman, and R G Bagin, and S Jagannath, and J M Vose, and G Spitzer, and A Kessinger, and K A Dicke, and J O Armitage
Gonadal function in Hodgkin's disease: long-term follow-up of chemotherapy.
December 1982, British medical journal (Clinical research ed.),
P J Bierman, and R G Bagin, and S Jagannath, and J M Vose, and G Spitzer, and A Kessinger, and K A Dicke, and J O Armitage
Long-term follow-up of two chemotherapy protocols in Hodgkin's disease.
January 1981, Medicina,
P J Bierman, and R G Bagin, and S Jagannath, and J M Vose, and G Spitzer, and A Kessinger, and K A Dicke, and J O Armitage
Long-term followup of health status in patients with severe rheumatoid arthritis after high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation.
August 2005, Arthritis and rheumatism,
Copied contents to your clipboard!